We are international

Sydney 2005:
Update on High Dose Therapy: MAG Studies
By Jean Paul Fermand, MD
Dr. Fermand represented the MAG group (Myelome-Autogreffe; Paris France). He presented long term follow up form the studies conducted from 1985-2005. Four trials were conducted: Pre-MAG, MAG 90, MAG 91, and MAG 95. Pre-MAG was a Phase 2 trial comparing early versus late HDT followed by SCT, results were similar in both arms. MAG 91 included older patients (55 to 66 years old); no significant differences were seen with OS. MAG 95 evaluated sequential HDT followed by a CD34 selection technique. Dr. Fermand presented the final analysis of this study at a median follow up of 73 months. Results show a significant overall survival advantage with double HDT versus single and CD34 selection showed no survival benefit. Dr. Femand shared the next study would investigate results in patients younger than 65.

Back to session summary

 related articles